Evolent Health (NYSE:EVH) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS

Evolent Health (NYSE:EVH) released its quarterly earnings data on Thursday. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35), Zacks reports. Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%.

Evolent Health Trading Up 1.8 %

EVH traded up $0.19 on Thursday, reaching $10.71. 2,588,197 shares of the company’s stock were exchanged, compared to its average volume of 2,146,734. The company’s 50 day moving average is $10.79 and its 200-day moving average is $18.98. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -11.77 and a beta of 1.45. Evolent Health has a twelve month low of $9.45 and a twelve month high of $35.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on EVH shares. UBS Group reduced their target price on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, January 16th. JPMorgan Chase & Co. reduced their target price on shares of Evolent Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Oppenheimer reduced their target price on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. Truist Financial reduced their target price on shares of Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Finally, Canaccord Genuity Group reduced their target price on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $17.92.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.